Sanofi Will Price U.S. Army-Developed Zika Vaccine To ‘Facilitate Access,’ Executive Says In Response To Criticism Over Exclusive License

STAT: Sanofi fires back at criticism of deal with Army for a Zika vaccine
“In response to criticism of its arrangement with the U.S. Army to produce a Zika virus vaccine, a Sanofi executive maintained the company is not pursuing the project based on ‘commercial return’ and intends to price the vaccine in order to ‘facilitate access’ in the interest of public health. The reassurances were offered in a May 22 letter sent to a House Energy and Commerce subcommittee amid mounting concerns the Army will offer Sanofi an exclusive license on two patents without receiving a commitment that a vaccine will be affordable for Americans whose tax dollars funded the discovery…” (Silverman, 5/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.